Related Experiment Videos
Idiopathic inflammatory myopathies: a treatment update
1Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, S703 Biomedical Science Tower, 3500 Terrace Street, Pittsburgh, PA 15261, USA. oddis@msx.dept-med.pitt.edu
Current Rheumatology Reports
|November 12, 2003
Summary
Corticosteroids are a primary treatment for inflammatory myopathies, but various immunosuppressive and biologic agents offer additional therapeutic options. Systemic and pulmonary involvement present challenges, and rehabilitation can improve patient outcomes.
Area of Science:
- Rheumatology
- Neurology
- Immunology
Background:
- Inflammatory myopathies are a group of debilitating neuromuscular disorders.
- Current treatments primarily rely on corticosteroids but have limitations.
Purpose of the Study:
- To review the diverse therapeutic landscape for inflammatory myopathies.
- To highlight challenges in managing systemic and pulmonary manifestations.
- To emphasize the role of rehabilitation in improving functional outcomes.
Main Methods:
- Comprehensive literature review of treatment modalities for inflammatory myopathies.
- Analysis of current therapeutic strategies, including corticosteroids, immunosuppressants, and biologics.
- Evaluation of management approaches for systemic and pulmonary complications.
Main Results:
- A wide range of immunosuppressive and biologic agents are available for myositis treatment.
- Pulmonary involvement significantly impacts morbidity and mortality.
- Rehabilitative measures can substantially enhance functional outcomes.
Conclusions:
- Treatment for inflammatory myopathies requires a multifaceted approach.
- Addressing systemic manifestations, particularly pulmonary issues, is critical.
- Integrating rehabilitation is essential for optimizing patient recovery and quality of life.